Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSoligenix Inc.

Soligenix Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.335 USD 0.00 ( 0.51%)
Last update at 2026-11-06T21:00:00Z
VOLUME
106852
Market Cap
7.84M

Momentum Score

…

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.35
High
52 Week Price Range
0.28
Low
2.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.33
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.07
ROE
-241.65%
Net Debt
-7.58M
ROCE
-209.29%
Diluted EPS TTM
-0.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.59M -8.68M -7.91M -14.95M -13.42M
Net income -11.08M -8.27M -6.14M -13.80M -12.55M
Selling general administrative 4.36M 4.22M 4.48M 6.69M 4.85M
Gross profit 0.00M -0.12M -0.74M 0.40M 0.10M
Reconciled depreciation 0.00M 0.01M 0.01M 0.02M 0.03M
Ebit -11.59M -9.46M -7.67M -14.11M -12.97M
Ebitda -11.58M -9.46M -7.67M -14.08M -12.90M
Depreciation and amortization 0.00M 0.01M 0.01M 0.03M 0.06M
Operating income -11.85M -9.44M -7.70M -14.11M -12.97M
Other operating expenses 11.85M 9.44M 7.70M 15.05M 13.79M
Interest expense - 0.21M 0.05M 0.82M 0.86M
Tax provision -0.51M -0.41M -1.16M -1.15M -0.86M
Net interest income 0.27M 0.21M -0.28M -0.82M -0.86M
Income tax expense -0.51M -0.41M -1.77M -1.15M -0.86M
Total revenue 0.00M 0.12M 0.84M 0.95M 0.82M
Total operating expenses 11.85M 9.32M 6.96M 14.50M 13.06M
Cost of revenue 0.00M 0.12M 0.74M 0.55M 0.73M
Total other income expense net 0.26M 0.76M -0.21M -0.85M -0.45M
Net income from continuing ops -11.08M -8.27M -8.07M -13.80M -12.55M
Net income applicable to common shares - - - - -12.55M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.24M 8.97M 9.80M 14.28M 26.87M
Other current assets 0.91M 1.01M 0.87M 0.27M 0.28M
Total liab 3.94M 4.85M 7.27M 16.75M 16.15M
Total stockholder equity 5.29M 4.12M 2.52M -2.47M 10.72M
Deferred long term liab - - - - 0.02M
Other current liab 2.47M 2.70M 2.67M 2.64M 3.26M
Common stock 0.01M 0.00M 0.01M 0.00M 0.04M
Capital stock 0.01M 0.00M 0.01M 0.00M 0.04M
Retained earnings -245.05M -233.97M -225.70M -219.56M -205.77M
Other assets - - - - 0.17M
Cash 7.94M 7.82M 8.45M 13.36M 26.04M
Total current liabilities 3.70M 4.85M 6.15M 16.52M 6.29M
Net debt -7.58M -6.33M -4.95M -3.12M -16.08M
Short term debt 0.11M 1.48M 2.37M 10.01M 0.11M
Short long term debt - 1.37M 2.25M 9.90M -
Short long term debt total 0.36M 1.48M 3.49M 10.24M 9.96M
Other stockholder equity 250.29M 238.04M 228.19M 217.06M 216.40M
Property plant equipment - - - - 0.13M
Total current assets 8.85M 8.83M 9.51M 13.85M 26.57M
Net tangible assets - - - - 10.72M
Net receivables - - 0.20M 0.22M 0.24M
Long term debt - - 1.01M - 9.86M
Inventory - - 0.00M - -
Accounts payable 1.12M 0.67M 1.11M 3.87M 2.93M
Accumulated other comprehensive income 0.05M 0.05M 0.02M 0.02M 0.04M
Non currrent assets other 0.03M 0.02M 0.02M 0.07M 0.17M
Non current assets total 0.39M 0.14M 0.29M 0.43M 0.30M
Capital lease obligations 0.36M 0.11M 0.23M 0.34M 0.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.00M -0.01M -0.01M
Change to liabilities - - - - 1.13M
Total cashflows from investing activities -0.01M - - - -0.01M
Net borrowings -1.37M -1.37M -7.00M - -0.01M
Total cash from financing activities 10.39M 7.76M 3.66M 0.08M 19.06M
Change to operating activities - - - - -0.54M
Net income -11.08M -8.27M -6.14M -13.80M -12.55M
Change in cash 0.12M -0.63M -4.91M -12.68M 7.37M
Begin period cash flow 7.82M 8.45M 13.36M 26.04M 18.68M
End period cash flow 7.94M 7.82M 8.45M 13.36M 26.04M
Total cash from operating activities -10.27M -8.40M -8.60M -12.65M -11.74M
Issuance of capital stock 12.16M 5.81M 11.67M 0.08M 19.71M
Depreciation 0.00M 0.01M 0.01M 0.02M 0.03M
Other cashflows from investing activities -0.01M - - - -
Dividends paid - - - -0.00M -
Change to account receivables - 0.22M 0.03M 0.02M 0.06M
Other cashflows from financing activities -0.71M 3.32M -0.92M -0.00M -0.64M
Change to netincome - - - - 0.08M
Capital expenditures 0.01M 0.00M 0.00M 0.01M 0.01M
Change in working capital 0.03M -0.35M -3.44M 0.43M 0.65M
Stock based compensation 0.59M 0.33M 0.37M 0.33M 0.36M
Other non cash items 0.19M -0.12M 0.60M 0.37M 0.19M
Free cash flow -10.27M -8.40M -8.60M -12.66M -11.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SNGX
Soligenix Inc.		 0.00
0.51%		 0.34 - 12.32 9.78 1.18 1.87 -0.12
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Soligenix Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

29 Emmons Drive, Princeton, NJ, United States, 08540

609 538 8200

https://www.soligenix.com

13

Name Title Year Born
Dr. Christopher J. Schaber Ph.D. Chairman of Directors, CEO & Pres 1966
Mr. Jonathan L. Guarino CPA, CGMA Sr. VP, CFO & Corp. Sec. 1973
Dr. Oreola Donini Ph.D. Sr. VP & Chief Scientific Officer 1972
Dr. Richard C. Straube M.D., MSc. Sr. VP & Chief Medical Officer 1952
Mr. Richard L. Dunning Exec. Officer 1946
Dr. Christopher J. Schaber Ph.D. Chairman of the Board of Directors, CEO & President 1966
Mr. Jonathan L. Guarino CPA, CGMA Senior VP, CFO & Corporate Secretary 1973
Dr. Oreola Donini Ph.D. Senior VP & Chief Scientific Officer 1972
Dr. Richard C. Straube M.D., MSc. Senior VP & Chief Medical Officer 1952
Mr. Adam T. Rumage Senior VP of Project Management & Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…